Acacia Pollen Agrostis Gigantea Pollen Ailanthus A
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Acacia Pollen Agrostis Gigantea Pollen Ailanthus A
- Multi-Allergen Immunotherapy Panel: Evaluation Report (Prediction Not Available)
Multi-Allergen Immunotherapy Panel: Evaluation Report (Prediction Not Available)
One-Sentence Summary
This submission contains a 45-component allergen extract mixture — including tree, grass, and weed pollens alongside botanical preparations such as Echinacea, goldenseal, fenugreek, and myrrh — which represents a multi-antigen immunotherapy panel rather than a single chemical entity. Because TxGNN operates on individual drug nodes matched via DrugBank IDs, no repurposing prediction could be generated for this mixture. The pipeline returned zero matched licenses, zero safety records, and zero predicted indications, making a standard evidence-based assessment impossible at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no regulatory records found) |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — and none was produced) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
This submission is not a single active pharmaceutical ingredient (API) but a panel of 45 distinct allergen components, comprising:
- Tree pollens (e.g., Acacia, Alnus, Fraxinus, Juglans, Juniperus, Liquidambar, Morus, Olea, Pinus, Platanus, Populus, Quercus, Salix, Ulmus)
- Grass pollens (e.g., Agrostis, Bromus spp., Cynodon, Dactylis, Festuca, Lolium, Phleum, Poa, Sorghum)
- Weed / shrub pollens (e.g., Amaranthus spp., Ambrosia spp., Atriplex, Chenopodium, Ligustrum, Phoenix, Plantago, Prosopis, Rumex, Salsola)
- Botanical preparations (Baptisia tinctoria root, Echinacea, Eucalyptus globulus, Fenugreek leaf, Goldenseal, Myrrh, Phytolacca americana root)
TxGNN requires a single DrugBank node to traverse the knowledge graph and generate disease predictions. Because this mixture has no DrugBank ID and cannot be collapsed into one pharmacological entity, the model has no entry point for graph traversal.
Additionally, several of the botanical components (Echinacea, goldenseal, myrrh, phytolacca) are herbal/immunomodulatory agents with uncertain mechanism-of-action data, further complicating any unified MOA-based analysis.
US Market Information
No US licenses or approved products were found for this multi-component panel under the submitted ingredient string.
Note: Individual allergen extracts (e.g., standardized Timothy grass pollen, short ragweed pollen) are regulated by the FDA Center for Biologics Evaluation and Research (CBER) as biological products, not via the NDA pathway. A targeted search through CBER’s allergenic product database or individual component submissions would be required.
Safety Considerations
Please refer to the package insert for safety information.
No drug–drug interaction records, key warnings, or contraindications were returned by any queried source for this mixture. Given the presence of potent immunomodulatory botanicals (Echinacea, goldenseal, phytolacca root), clinicians should exercise caution in immunocompromised patients and those on concurrent immunosuppressants.
Conclusion and Next Steps
Decision: Hold
Rationale: The submission cannot be evaluated under the standard TxGNN repurposing framework because the input is a heterogeneous 45-component allergen panel with no single DrugBank ID, no original indication records, and no generated predictions. All three data sources queried (TFDA, DDI database, DrugBank) returned either zero results or incomplete matches.
To proceed, the following is needed:
- Decompose the mixture: Submit each component (or clinically meaningful sub-panels, e.g., grass pollen group) as individual TxGNN queries to obtain per-ingredient predictions.
- Resolve the DrugBank ID gap: Map individual allergen components (especially the botanical preparations: Echinacea, Goldenseal, Fenugreek, Myrrh, Phytolacca) to their respective DrugBank entries.
- Clarify clinical context: Determine whether the intended use is allergy immunotherapy (subcutaneous/sublingual desensitisation) or allergy diagnostic testing, as these require separate evaluation frameworks.
- Search CBER allergen product database: For US market status, query the FDA CBER allergen extract product listings rather than the NDA/ANDA pathway.
- Obtain MOA documentation: For the botanical components with immunomodulatory claims, retrieve mechanism data from DrugBank, EMA herbal monographs, or WHO monographs on herbal medicines.
- Address Blocking data gap DG001: Obtain and parse local regulatory package insert PDFs (or equivalent CBER product information sheets) before any safety screening can proceed.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.